Browse & search snapshots

Notice of intent to amend: Prescription Drug List (PDL): Tramadol March 31, 2021 Our file number: 21-106063-491 The Prescription Drug List (PDL) is a list of medicinal ingredients that when found in a drug, require a prescription. It does not include medicinal ingredients that…

Notice of Consultation on the Prescription Drug List (PDL): Metamizole (dipyrone) April 23, 2021 Our file number: 21-107779-356 This Notice of Consultation provides an opportunity to comment on the proposal to add metamizole (also known as ‘dipyrone’) to the Prescription Drug…

Scientific Advisory Committee on Health Products for Women (SAC-HPW): Summary of Findings and Advice, October 29 and 30, 2020 Virtual Meeting Context The Medical Devices Action Plan (MDAP) Footnote 1 was launched in December 2018 to communicate on Health Canada's strategies to…

Scientific Advisory Committee on Health Products for Women (SAC-HPW): Agenda Date and Time: Thursday October 29, 2020, 12:30pm to 3:30 pm EST; Friday October 30, 2020, 12:30pm to 4:30 pm EST Location: Virtual Chairpersons: Lorraine Greaves (Chair), Louise Pilote (Vice-chair)…

Consultation on the draft Issue Identification Paper: Drug-device combination products Current status: Closed This consultation ran from April 6, 2021 to June 7, 2021. See the “What we heard” report for summaries of the discussions that took place. Drug-device combination…

Notice: Prescription Drug List (PDL): Multiple Additions Date: May 27, 2021 Our file number: 21-110028-562 The purpose of this Notice of Amendment is to notify about the additions of: Strain Russian BCG-I to the "including (but not limited to)" column of the |Bacillus…

Notice: Phase II of the XML PM Project (Product Monograph in the Extensible Markup Language Format) May 28, 2021 Phase II: Full Production (Voluntary) In April 2019, Health Canada announced its intent to transition product monograph templates to a structured format based on XML…

Ils remercient les aînés autochtones, les membres de la communauté et les chercheurs d’entretenir un dialogue constant avec eux afin de renforcer davantage la recherche en santé autochtone au Canada.

ARCHIVED - Notice to Stakeholders – Clarification of Requirements Under the Food and Drug Regulations When Conducting Clinical Research With Cannabis We are revising this notice to reflect Health Canada’s new framework on non-therapeutic cannabis research. For more information on…

Guidance Document: Data Protection under C.08.004.1 of the Food and Drug Regulations Document Change Log Document Change Log Date Change Location (section, paragraph) Nature of and/or Reason for Change 2025/06/16 Updated to clarify current practices Throughout Updated to clarify…